GlassScriptPhysician profile
Mina M Megalla
NPI 1093195356
$679.68
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $101 · 2021: $186 · 2022: $178 · 2023: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $114.70 | 2020-2023 | Slynd |
| Daiichi Sankyo INC. | $69.54 | 2020-2021 | |
| Evofem Biosciences, INC. | $66.20 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $52.69 | 2019-2020 | |
| Abbvie INC. | $49.74 | 2019-2022 | |
| Agile Therapeutics, INC. | $40.56 | 2021 | |
| Myovant Sciences INC. | $40.18 | 2021-2022 | |
| Pfizer INC. | $35.69 | 2020-2023 | |
| Dysis Medical, INC. | $32.61 | 2022 | |
| Mayne Pharma Commercial LLC | $32.52 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.15 | 2022 | |
| Roche Diagnostics Corporation | $22.93 | 2021 | |
| Aspira Women'S Health INC | $17.29 | 2019 | |
| Organon LLC | $15.71 | 2023 | Nexplanon |
| Celularity INC. | $14.81 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $13.08 | 2019 | |
| Lupin INC. | $12.69 | 2019 | |
| Avion Pharmaceuticals | $12.41 | 2022 | |
| Allergan, INC. | $12.17 | 2019 | |
| Alydia Health | $1.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Megalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.